MedTrace Logo

Pharmacogenetic Clinical Trial of Nepicastat for Post Traumatic Stress Disorder (PTSD)

NCT00641511 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2019-08-21

No results posted yet for this study

Summary

Assess the effect of nepicastat in the treatment of in Post Traumatic Stress Disorder (PTSD) in conflict or combat zone experienced veterans, in comparison to placebo.

Conditions

  • Post Traumatic Stress Disorder (PTSD)

Interventions

DRUG

SYN117 (nepicastat)

120 mg per day

DRUG

Placebo comparator

once per day placebo capsules

Sponsors & Collaborators

  • Tuscaloosa Veterans Affairs Medical Center

    collaborator FED

  • Ralph H. Johnson VA Medical Center

    collaborator FED

  • Acorda Therapeutics

    collaborator INDUSTRY

  • Michael E. DeBakey VA Medical Center

    lead FED

Principal Investigators

  • Thomas Kosten, MD · Baylor College of Medicine, and DeBakey VAMC

  • Lori Davis, MD · Tuscaloosa VAMC

  • Mark Hamner, MD · Ralph H Johnson VAMC

  • David P. Graham, MD · Michael E. DeBakey VA Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-09-30
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00641511 on ClinicalTrials.gov